Drug
Zamicastat clinical trials
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2018 (7)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2015 | 2 |
| 2018 | 7 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Furosemide (1) · PNU-100480 (1) · Sildenafil (1) · Warfarin (1) · Bosentan (1) · Treprostinil (1)
Studies
Open first, then newest update. How each study uses zamicastat is read from its arms, and is right about nine times in ten.
Testing it · 12
- Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and FurosemideCompletedPhase 1Bial - Portela C S.A.NCT07173738Written as BIA 5-1058
- Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)CompletedPhase 2Bial - Portela C S.A.NCT04316143Written as Oral zamicastat
- Safety and Efficacy of BIA 5-1058 in PAHCompletedPhase 2Bial - Portela C S.A.NCT06009185Written as Oral zamicastat
- Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of SildenafilCompletedPhase 1Bial - Portela C S.A.NCT04994860Written as BIA 5-1058
- Effect of BIA 5-1058 400 mg on Warfarin PharmacokineticsCompletedPhase 1Bial - Portela C S.A.NCT04994119Written as BIA 5-1058
- Effect of Food on BIA 5-1058CompletedPhase 1Bial - Portela C S.A.NCT04991155Written as BIA 5-1058
- Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of BosentanCompletedPhase 1Bial - Portela C S.A.NCT04991207Written as BIA 5-1058
- Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058TerminatedPhase 1Bial - Portela C S.A.NCT04991194Written as BIA 5-1058
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058CompletedPhase 1Bial - Portela C S.A.NCT03708146Written as BIA 5-1058
- Effect of BIA 5 1058 on Cardiac RepolarizationCompletedPhase 1Bial - Portela C S.A.NCT03489005Written as BIA 5-1058
- Effect of BIA 5-1058 on the Steady State Pharmacokinetics of TreprostinilCompletedPhase 1Bial - Portela C S.A.NCT04675944Written as BIA 5-1058
- Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.CompletedPhase 1Bial - Portela C S.A.NCT02151994Written as BIA 5-1058
Codes
What other systems call zamicastat · ClinicalTrials.gg INT001059
- MeSH (NLM) C000630084zamicastatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) YLU32D0DNVZAMICASTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27294585zamicastatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152947ZamicastatOne source FDA
- DrugBank DB12389One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630084 | zamicastat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | YLU32D0DNV | ZAMICASTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27294585 | zamicastat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152947 | Zamicastat | One source FDA |
| DrugBank | DB12389 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.